The most effective new therapy ever discovered for the treatment of hepatitis C will never see the light of day unless we are able to convince big pharma giant Gilead Sciences to move forward at once with this development. This treatment combines Bristol-Myers Squibb drug daclatasvir and Gilead’s GS-7977 (now named sofosbuvir). Together these two drugs cured 100% of the most prevalent type of hepatitis C (genotype 1)